Company intelligence / Profile preview

Otsuka Pharmaceutical Co., Ltd.

Ownership: Public · 4578
Employees: ~5634
Development stage: Commercial

Overview

Otsuka has successfully developed antipsychotic agents including Abilify Asimtufii and Rexulti, which have shown significant sales growth. Recently received FDA clearance for Rejoyn, the first prescription digital therapeutic for adjunctive treatment of major depressive disorder.

Therapeutic areas: Psychiatry
Modalities: Small moleculesDigital therapeutics
Industry: Biotech

Drug pipeline

29 assets

centanafadine

Approved

28 more assets in the full pipeline.

Partnerships

Lundbeck (for Abilify Asimtufii and Rexulti)Click Therapeutics (for Rejoyn)Mindset Pharma (acquired)

Beyond the preview

Go deeper on Otsuka Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otsuka Pharmaceutical Co., Ltd..